Page last updated: 2024-08-17

quinoxalines and eapb0503

quinoxalines has been researched along with eapb0503 in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Bompart, J; Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; El Messaoudi, S; Gattacceca, F; Khier, S; Lafaille, F; Pinguet, F; Solassol, I1
Bertrand, B; Bonnet, PA; Bressolle, FM; Deleuze-Masquéfa, C; Doulain, PE; Enjalbal, C; Lafaille, F; Solassol, I; Vappiani, J1
Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El Eit, R; Hmadi, R; Iskandarani, A; Mahon, FX; Nasr, R; Saliba, J1
Berthier, CP; Bonnet, PA; Deleuze-Masquefa, C; El Hajj, HA; Hamie, MH; Hleihel, RS; Karam, MM; Nabbouh, AI; Saliba, JL; Tawil, NM; Wu, HJM1
Bec, N; Constant, C; Courbet, A; Deleuze-Masquefa, C; El Messaoudi, S; Gattacceca, F; Khier, S; Larroque, C; Pugniere, M; Zghaib, Z1
Bonnet, PA; Bressolle-Gomeni, FMM; Chouchou, A; Cuq, P; Deleuze-Masquéfa, C; Enjalbal, C; Marion, B; Roques, C1
Bastien, P; Bonnet, PA; Bou Youness, H; El Hajj, H; El Hajj, R; Khalifeh, I; Lachaud, L; Masquefa, C1
Bonnet, PA; Deleuze-Masquefa, C; El Hajj, H; El Hajj, R; El Sabban, M; Hamie, M; Hleihel, R; Jishi, B; Skayneh, H1

Other Studies

8 other study(ies) available for quinoxalines and eapb0503

ArticleYear
Metabolism and pharmacokinetics of EAPB0203 and EAPB0503, two imidazoquinoxaline compounds previously shown to have antitumoral activity on melanoma and T-lymphomas.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:10

    Topics: Animals; Antineoplastic Agents; Biotransformation; Blood Proteins; Dogs; Humans; Lymphoma, T-Cell; Melanoma; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Quinoxalines; Rats; Rats, Sprague-Dawley; Species Specificity; Spectrometry, Mass, Electrospray Ionization; Tissue Distribution

2010
Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry.
    Journal of pharmaceutical and biomedical analysis, 2014, Volume: 88

    Topics: Animals; Antineoplastic Agents; Cells, Cultured; Chemistry, Pharmaceutical; Chromatography, Liquid; Deuterium Exchange Measurement; Dogs; Hepatocytes; Humans; Hydroxylation; Microsomes, Liver; Quinoxalines; Rats; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2014
EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.
    Anti-cancer drugs, 2014, Volume: 25, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Pyrimidines; Quinoxalines

2014
Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Cancer, 2017, 05-01, Volume: 123, Issue:9

    Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cytoplasm; Flow Cytometry; Humans; Immunoblotting; Leukemia, Myeloid, Acute; Mice; Microscopy, Confocal; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinoxalines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017
Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Colchicine; Computer Simulation; Humans; Models, Molecular; Molecular Docking Simulation; Protein Binding; Quinoxalines; Tubulin; Tubulin Modulators

2017
Liquid chromatography-electrospray ionization-tandem mass spectrometry method for quantitative estimation of new imiqualine leads with potent anticancer activities in rat and mouse plasma. Application to a pharmacokinetic study in mice.
    Journal of pharmaceutical and biomedical analysis, 2018, Jan-30, Volume: 148

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Humans; Liquid-Liquid Extraction; Male; Mice; Mice, Inbred C57BL; Plasma; Quinoxalines; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry

2018
EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.
    PLoS neglected tropical diseases, 2018, Volume: 12, Issue:11

    Topics: Humans; Imiquimod; Leishmania major; Leishmania tropica; Leishmaniasis, Cutaneous; NF-kappa B; Quinoxalines; Syria; Toll-Like Receptors

2018
EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.
    International journal of molecular sciences, 2022, Mar-22, Volume: 23, Issue:7

    Topics: Animals; Cysteine Endopeptidases; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Nuclear Proteins; Nucleophosmin; Quinoxalines; Sumoylation

2022